Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 

LCT Receives Funds from Pharmaceutical Investor

9 March 2011

LCT Receives Funds from Pharmaceutical Investor

9 March 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY), a global company pioneering the development of a cell implant therapy to treat diabetes, confirmed today the receipt of A$1.7 million from Jiangsu Aosaikang Pharmaceutical Co., Ltd (ASK) in return for 14,334,080 shares which is 4.7% of the company's shares.

ASK is a private research-based pharmaceutical company, based in Nanjing, China. Established in 2005, ASK develops, produces and markets pharmaceuticals and healthcare products, and has over sixty pharmaceutical products in the market place. The Placement was announced on 31 January 2011.

LCT CEO Dr Ross Macdonald said: "We are very pleased to welcome Jiangsu Aosaikang Pharmaceutical as a strategic investor in LCT. The funding will allow us to progress development and clinical trials of our breakthrough lead product DIABECELL(r), for the treatment of Type 1 diabetes."

As announced in January, in addition to ASK's investment the companies have also agreed to negotiate a collaborative research agreement, the terms of which are proposed to include LCT granting ASK a right of first refusal to negotiate a licence to commercialise the use of DIABECELL in China and become the sole agency to implant and treat patients with DIABECELL once the product is registered in China.

ENDS

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Business Headlines | Sci-Tech Headlines

 
 
 
 
 
 
 
 
 
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.